NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES

Novel pyrrazolopyridines according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prophylaxis and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, all...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	HODGES, ALASTAIR JAMES, MENET, CHRISTEL JEANNE MARIE, VATER, HUW DAVID
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Novel pyrrazolopyridines according to Formula I, able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prophylaxis and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. La présente invention concerne de nouvelles pyrrazolopyridines de formule I, pouvant inhiber la kinase JAK. Ces composés peuvent être préparés sous forme de composition pharmaceutique, et peuvent être utilisés pour la prophylaxie et le traitement d'une variété de pathologies chez les mammifères dont les humains, comprenant entre autres, l'allergie, les pathologies inflammatoires, les maladies auto-immunes, les maladies prolifératives, le rejet de greffe, les maladies impliquant une déficience du renouvellement du cartilage, des malformations congénitales du cartilage, et/ou des maladies associées à l'hyper-sécrétion d'IL6 ou d'interférons.